Incyte Corp (INCY)

112.02
3.00 2.60
NASDAQ : Health Care
Prev Close 115.05
Open 114.36
Day Low/High 111.54 / 115.48
52 Wk Low/High 55.00 / 133.62
Volume 886.57K
Avg Volume 1.29M
Exchange NASDAQ
Shares Outstanding 210.65M
Market Cap 24.20B
EPS 0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Incyte Announces Pricing Of Public Offering Of 4,945,000 Shares Of Common Stock

Incyte Announces Pricing Of Public Offering Of 4,945,000 Shares Of Common Stock

Incyte Corporation (Nasdaq: INCY) (the "Company") today announced the pricing of its underwritten public offering of 4,945,000 shares of its common stock.

Incyte Announces Proposed Public Offering Of 4,945,000 Shares Of Common Stock

Incyte Announces Proposed Public Offering Of 4,945,000 Shares Of Common Stock

Incyte Corporation (Nasdaq: INCY) (the "Company") today announced that the Company intends to offer to sell, subject to market and other conditions, 4,945,000 shares of its common stock in an underwritten public offering.

Actor Finola Hughes And Dr. Ellen Ritchie Discuss The Symptoms Of Polycythemia Vera

Actor Finola Hughes And Dr. Ellen Ritchie Discuss The Symptoms Of Polycythemia Vera

Incyte Corporation (NASDAQ:INCY) is proud to recognize and support the patients of the MPN community throughout September in honor of Blood Cancer Awareness Month.

New Data For Epacadostat In Combination With KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses In Patients With Advanced Melanoma

New Data For Epacadostat In Combination With KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses In Patients With Advanced Melanoma

Incyte Corporation (Nasdaq:INCY) today announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1214O) containing new and updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating...

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

The San Diego firm said a Phase 3 study of Otividex in patients with Meniere's disease missed its primary endpoint.

Forbes Magazine Names Incyte One Of The World's Most Innovative Companies For Third Consecutive Year

Forbes Magazine Names Incyte One Of The World's Most Innovative Companies For Third Consecutive Year

Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 6th  on  Forbes magazine's 2017 list of the World's Most Innovative Companies.

Incyte Reports 2017 Second-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Reports 2017 Second-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2017 second-quarter financial results, highlighting strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Itacitinib For Acute Graft-Versus-Host Disease

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Itacitinib For Acute Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-301, a pivotal Phase 3 trial for the first-line treatment of patients with acute graft-versus-host disease (GVHD).

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)

'Blind side' competition is playing havoc with some highly visible companies, says Jim Cramer. You can't compete with free.

Alexion Pharmaceuticals, Incyte, Walt Disney: 'Mad Money' Lightning Round

Alexion Pharmaceuticals, Incyte, Walt Disney: 'Mad Money' Lightning Round

Jim Cramer's bullish on Alexion Pharmaceuticals and Incyte. But, he says, Disney's good for the long term.

Incyte To Report Second Quarter Financial Results

Incyte To Report Second Quarter Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 10:00 a.

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

New Safety And Long-Term Efficacy Data From Baricitinib Clinical Trials In Patients With Moderate-to-Severe Rheumatoid Arthritis Presented At EULAR 2017

- Pooled analysis of eight clinical trials shows no difference in serious infection events compared to placebo

Domino's Pizza, Xylem, Incyte, Mercadolibre: 'Mad Money' Lightning Round

Domino's Pizza, Xylem, Incyte, Mercadolibre: 'Mad Money' Lightning Round

Jim Cramer is bullish on Domino's Pizza, Xylem, and Incyte, but he's waiting for better pricing for NXP Semiconductor.

Navigating Strong Crosscurrents: Cramer's 'Mad Money' Recap (Tuesday 6/13/17)

Navigating Strong Crosscurrents: Cramer's 'Mad Money' Recap (Tuesday 6/13/17)

Jim Cramer says the markets could be further rattled by the Federal Reserve meeting.

Lilly To Present New Data On Olumiant® (baricitinib) In Rheumatoid Arthritis And Taltz® (ixekizumab) In Psoriatic Arthritis At The Annual European Congress Of Rheumatology (EULAR 2017)

Lilly to share 31 abstracts, including 27 abstracts detailing safety, efficacy and patient outcomes data for Olumiant and Taltz

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Goldman Sachs 38 th Annual Global Healthcare Conference on Wednesday,...

Incyte Cancer Drug Data Is 'Compelling,' Credit Suisse Says

Incyte Cancer Drug Data Is 'Compelling,' Credit Suisse Says

Credit Suisse analyst Alethia Young isn't worried about Incyte.

Incyte Analyst And Investor Event To Highlight Clinical Data Presentations From ASCO 2017

Incyte Corporation (Nasdaq:INCY) announced today that data from ongoing investigational studies of epacadostat in combination with pembrolizumab (ECHO-202) and nivolumab (ECHO-204) in multiple tumor types will be discussed...

Clinical Trial Data For Combination Of Epacadostat And Opdivo® (nivolumab) Demonstrate Durable Clinical Responses In Patients With Melanoma And Head And Neck Cancer

Incyte Corporation (Nasdaq:INCY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced updated data from the ongoing Phase 1/2 ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte's investigational...

Updated Data From ECHO-202 Trial Of Incyte's Epacadostat In Combination With Merck's KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity Across Multiple Tumor Types

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte's...

Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study

Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study

Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO.

Combination Of Incyte's Epacadostat Plus Merck's KEYTRUDA® (pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing Phase...

TheStreet Quant Rating: C- (Hold)